{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T03:02:36Z","timestamp":1780628556673,"version":"3.54.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,4]]},"DOI":"10.7759\/cureus.110271","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T02:07:51Z","timestamp":1780625271000},"source":"Crossref","is-referenced-by-count":0,"title":["Microscopic Polyangiitis With Temporal Artery Involvement Mimicking Giant Cell Arteritis"],"prefix":"10.7759","author":[{"given":"Janhvi","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith A","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac623","article-title":"Diagnosing and treating ANCA-associated vasculitis: an updated review for clinical practice","volume":"62","author":"Chevet B","year":"2023","unstructured":"Chevet B, Cornec D, Casal Moura M, et al.. Diagnosing and treating ANCA-associated vasculitis: an updated review for clinical practice. Rheumatology (Oxford). 2023, 62:1787-803. 10.1093\/rheumatology\/keac623","journal-title":"Rheumatology (Oxford)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01736-1","article-title":"Diagnosis and management of ANCA-associated vasculitis","volume":"403","author":"Kronbichler A","year":"2024","unstructured":"Kronbichler A, Bajema IM, Bruchfeld A, Mastroianni Kirsztajn G, Stone JH. Diagnosis and management of ANCA-associated vasculitis. Lancet. 2024, 403:683-98. 10.1016\/S0140-6736(23)01736-1","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/art.41527","article-title":"Temporal arteritis revealing antineutrophil cytoplasmic antibody-associated vasculitides: a case-control study","volume":"73","author":"Delaval L","year":"2021","unstructured":"Delaval L, Samson M, Schein F, et al.. Temporal arteritis revealing antineutrophil cytoplasmic antibody-associated vasculitides: a case-control study. Arthritis Rheumatol. 2021, 73:286-94. 10.1002\/art.41527","journal-title":"Arthritis Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2007.01.009","article-title":"Microscopic polyangitis presenting with temporal arteritis and multiple cranial neuropathies","volume":"256","author":"Morinaga A","year":"2007","unstructured":"Morinaga A, Ono K, Komai K, Yamada M. Microscopic polyangitis presenting with temporal arteritis and multiple cranial neuropathies. J Neurol Sci. 2007, 256:81-3. 10.1016\/j.jns.2007.01.009","journal-title":"J Neurol Sci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199601000-00003","article-title":"Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients","volume":"75","author":"Guillevin L","year":"1996","unstructured":"Guillevin L, Lhote F, Gayraud M, et al.. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore). 1996, 75:17-28. 10.1097\/00005792-199601000-00003","journal-title":"Medicine (Baltimore)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e318205a4c6","article-title":"The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort","volume":"90","author":"Guillevin L","year":"2011","unstructured":"Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Toumelin PL. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore). 2011, 90:19-27. 10.1097\/MD.0b013e318205a4c6","journal-title":"Medicine (Baltimore)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24634","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"73","author":"Chung SA","year":"2021","unstructured":"Chung SA, Langford CA, Maz M, et al.. 2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res (Hoboken). 2021, 73:1088-105. 10.1002\/acr.24634","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002368","article-title":"Description and validation of histological patterns and proposal of a dynamic model of inflammatory infiltration in giant-cell arteritis","volume":"95","author":"Hern\u00e1ndez-Rodr\u00edguez J","year":"2016","unstructured":"Hern\u00e1ndez-Rodr\u00edguez J, Murgia G, Villar I, et al.. Description and validation of histological patterns and proposal of a dynamic model of inflammatory infiltration in giant-cell arteritis. Medicine (Baltimore). 2016, 95:e2368. 10.1097\/MD.0000000000002368","journal-title":"Medicine (Baltimore)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2014.01.023","article-title":"The diagnosis and classification of microscopic polyangiitis","volume":"48-49","author":"Kallenberg CG","year":"2014","unstructured":"Kallenberg CG. The diagnosis and classification of microscopic polyangiitis. J Autoimmun. 2014, 48-49:90-3. 10.1016\/j.jaut.2014.01.023","journal-title":"J Autoimmun"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11010275","article-title":"Temporal artery vascular diseases","volume":"11","author":"Greigert H","year":"2022","unstructured":"Greigert H, Ramon A, Tarris G, Martin L, Bonnotte B, Samson M. Temporal artery vascular diseases. J Clin Med. 2022, 11:275. 10.3390\/jcm11010275","journal-title":"J Clin Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich B","year":"2024","unstructured":"Hellmich B, Sanchez-Alamo B, Schirmer JH, et al.. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2024, 83:30-47. 10.1136\/ard-2022-223764","journal-title":"Ann Rheum Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.10.008","article-title":"KDIGO 2024 clinical practice guideline for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) ANCA Vasculitis Work Group","year":"2024","unstructured":"Kidney Disease. Improving Global Outcomes (KDIGO) ANCA Vasculitis Work Group: KDIGO 2024 clinical practice guideline for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Kidney Int. 2024, 105:S71-116. 10.1016\/j.kint.2023.10.008","journal-title":"Kidney Int"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone JH","year":"2010","unstructured":"Stone JH, Merkel PA, Spiera R, et al.. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010, 363:221-32. 10.1056\/NEJMoa0909905","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones RB","year":"2010","unstructured":"Jones RB, Tervaert JW, Hauser T, et al.. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010, 363:211-20. 10.1056\/NEJMoa0909169","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne DR","year":"2021","unstructured":"Jayne DR, Merkel PA, Schall TJ, Bekker P. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021, 384:599-609. 10.1056\/NEJMoa2023386","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae689","article-title":"Drug-induced liver injury related to avacopan therapy","volume":"64","author":"Mori K","year":"2025","unstructured":"Mori K, Shirai T, Mutoh T, et al.. Drug-induced liver injury related to avacopan therapy. Rheumatology (Oxford). 2025, 64:2533-40. 10.1093\/rheumatology\/keae689","journal-title":"Rheumatology (Oxford)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2025.12.017","article-title":"Profiling of potential postmarket risk tracking and pharmacovigilance data for avacopan","volume":"48","author":"Zhou Z","year":"2026","unstructured":"Zhou Z, Yu L, Zheng J, He Y, Xia L, Jia Q, Liu L. Profiling of potential postmarket risk tracking and pharmacovigilance data for avacopan. Clin Ther. 2026, 48:247-57. 10.1016\/j.clinthera.2025.12.017","journal-title":"Clin Ther"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2010.07.006","article-title":"Predictive factors of response to rituximab therapy in rheumatoid arthritis: what do we know today?","volume":"9","author":"Benucci M","year":"2010","unstructured":"Benucci M, Manfredi M, Puttini PS, Atzeni F. Predictive factors of response to rituximab therapy in rheumatoid arthritis: what do we know today?. Autoimmun Rev. 2010, 9:801-3. 10.1016\/j.autrev.2010.07.006","journal-title":"Autoimmun Rev"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker266","article-title":"Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials","volume":"50","author":"Suppiah R","year":"2011","unstructured":"Suppiah R, Hadden RD, Batra R, et al.. Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials. Rheumatology (Oxford). 2011, 50:2214-22. 10.1093\/rheumatology\/ker266","journal-title":"Rheumatology (Oxford)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13154298","article-title":"Aural manifestations of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis-diagnosis, symptoms, treatment","volume":"13","author":"Kaczmarczyk MS","year":"2024","unstructured":"Kaczmarczyk MS, Jurkiewicz D, Niemczyk S, Rymarz A. Aural manifestations of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis-diagnosis, symptoms, treatment. J Clin Med. 2024, 13:4298. 10.3390\/jcm13154298","journal-title":"J Clin Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/493217-microscopic-polyangiitis-with-temporal-artery-involvement-mimicking-giant-cell-arteritis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T02:07:52Z","timestamp":1780625272000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/493217-microscopic-polyangiitis-with-temporal-artery-involvement-mimicking-giant-cell-arteritis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.110271","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,4]]}}}